(MedPage Today) — ORLANDO — The investigational interleukin (IL)-6 inhibitor vamikibart led to visual improvements in uveitic macular edema in two identical phase III trials, with one exception.
In the MEERKAT trial, the adjusted proportion…
Source link : https://www.medpagetoday.com/meetingcoverage/aao/118057
Author :
Publish date : 2025-10-21 14:42:00
Copyright for syndicated content belongs to the linked Source.
